Abstract
The forkhead box O family consists of FoxO1, FoxO3, FoxO4 and FoxO6 proteins in mammals. Expressed ubiquitously in the body, the four FoxO isoforms share in common the amino DNA-binding domain, known as ‘forkhead box’ domain. They mediate the inhibitory action of insulin or insulin-like growth factor on key functions involved in cell metabolism, growth, differentiation, oxidative stress, senescence, autophagy and aging. Genetic mutations in FoxO genes or abnormal expression of FoxO proteins are associated with metabolic disease, cancer or altered lifespan in humans and animals. Of the FoxO family, FoxO6 is the least characterized member and is shown to play pivotal roles in the liver, skeletal muscle and brain. Altered FoxO6 expression is associated with the pathogenesis of insulin resistance, dietary obesity and type 2 diabetes and risk of neurodegeneration disease. FoxO6 is evolutionally divergent from other FoxO isoforms. FoxO6 mediates insulin action on target genes in a mechanism that is fundamentally different from other FoxO members. Here, we focus our review on the role of FoxO6, in contrast with other FoxO isoforms, in health and disease. We review the distinctive mechanism by which FoxO6 integrates insulin signaling to hepatic glucose and lipid metabolism. We highlight the importance of FoxO6 dysregulation in the dual pathogenesis of fasting hyperglycemia and hyperlipidemia in diabetes. We review the role of FoxO6 in memory consolidation and its contribution to neurodegeneration disease and aging. We discuss the potential therapeutic option of pharmacological FoxO6 inhibition for improving glucose and lipid metabolism in diabetes.
The forkhead box O family
The forkhead box O (FoxO) family consists of FoxO1 (FKHR), FoxO3 (FKHRL1), FoxO4 (AFX) and FoxO6 proteins, each encoded by a distinct gene in mammalian cells. These four isoforms share a common structural motif, namely the ‘forkhead box’ or ‘winged helix’ domain that is responsible for binding to chromatin DNA in the nucleus of cells (Accili & Arden 2004). FoxO proteins act as nuclear transcription factors that mediate the inhibitory action of insulin or insulin-like growth factor (IGF-1) on key functions in diverse pathways including cell metabolism, proliferation, differentiation, oxidative stress, cell survival and senescence, autophagy and aging in mammals (Accili & Arden 2004). As a result, genetic mutations in FoxO genes or altered expression of FoxO proteins are associated with diseases including diabetes and cancer or with reduced lifespan in mammals. This latter aspect is exemplified by the illustration of role of the FoxO ortholog Daf16 in Caenorhabditis elegans (Lee et al. 2003, Hwangbo et al. 2004). Daf16 mediates the effect of insulin-like receptor Daf-2 on cellular anti-oxidative functions (Essers et al. 2005, Mueller et al. 2014). Increased Daf16 expression, resulting from attenuated insulin-like signaling or increased oxidative stress, promotes anti-oxidative function, contributing to the lifespan extension in Caenorhabditis elegans (Lee et al. 2003). Likewise, the FoxO1 ortholog dFoxO signaling through insulin-like receptor dInR contributes to the regulation of longevity in Drosophila melanogaster (Hwangbo et al. 2004).
Among the four FoxO isoforms in mammalian cells, FoxO6 remains the least characterized member. FoxO6 has garnered less interest, due in part to the misconception that FoxO6 expression is confined in the brain (Jacobs et al. 2003). Subsequent research has rectified this misconception, showing that FoxO6 is expressed in central and peripheral tissues including the liver, intestine, lung, kidney, muscle and adipose tissues, a broad tissue distribution that is characteristic of other FoxO isoforms in mammals (Kim et al. 2011). Recent studies indicate that FoxO6 plays important roles in integrating insulin signaling to glucose and lipid metabolism. However, unlike other FoxO isoforms, FoxO6 mediates insulin action on target gene expression in cells via a distinct mechanism that is fundamentally different from the FoxO family (Kim et al. 2011). This is consistent with the distinctive feature of FoxO6 protein (Fig. 1). FoxO6 expression becomes deregulated in metabolic disease. Furthermore, altered FoxO6 expression in the brain is associated with impaired cognitive function in mice. In this article, we provide a comprehensive review on the role of FoxO6 in insulin action and carbohydrate metabolism in the liver. We provide mechanistic insight into the distinct mechanism by which insulin differentially modulates the transcriptional activity of FoxO6, as opposed to other members in the FoxO family. We discuss how FoxO6 deregulation in the liver contributes to the development of metabolic abnormalities in animal models with obesity and type 2 diabetes. We also review nascent evidence that FoxO6 plays important roles in neuronal cells with its potential contribution to neurodegeneration and longevity.
Schematic depiction of the mouse FoxO6 protein. FoxO6 is characterized by its amino DNA-binding and carboxyl trans-activation domains. Within the DNA-binding domain are the bipartite nuclear localization signal (NLS), consensus 14-3-3 protein-binding motif and two conserved Akt/PKB phosphorylation sites T26 and S184. Amino acid residues K173, K176, K190, K202 and K229 denote five distinct acetylation sites that are conserved across the species.
Citation: Journal of Endocrinology 233, 2; 10.1530/JOE-17-0002
FoxO integration of insulin signaling to target gene expression
FoxO proteins or FoxO orthologs (Daf16 and dFoxO) are the class of transcrption factors that mediates the inhibitory action of insulin or insulin-like growth factor (IGF-1) on target genes in cells. It is well characterized that insulin (or IGF-1) exerts its inhibitory effect on gene expression via a highly conserved sequence (TG/ATTTT/G), known as the ‘insulin responsive element’ (IRE) in target promoters (Accili & Arden 2004). In response to attenuated insulin (or IGF-1) signaling, FoxO proteins or FoxO orthologs become active in the nucleus and bind as trans-activators to the IRE DNA motif within target gene promoters to stimulate target gene expression. In keeping with this action, FoxO proteins or FoxO orthologs possess the amino forkhead box domain for binding to chromatin DNA and the carboxyl transactivation domain for enhancing promoter activity. Crystallographic studies reveal that FoxO proteins bind as monomers to chromatin DNA (Brent et al. 2008). In response to increased insulin (or IGF-1) signaling, FoxO proteins or FoxO orthologs undergo insulin-mediated phosphorylation and translocation from the nucleus to the cytoplasm, resulting in the inhibition of target gene expression (Accili & Arden 2004). This phosphorylation-dependent nucleocytoplasmic trafficking serves as an effective mechanism by which insulin (or IGF-1) regulates FoxO transcriptional activity in cells. All members of the FoxO family, with the exception of FoxO6, undergo insulin-dependent phosphorylation and nuclear exclusion. Failure in insulin (or IGF-1)-mediated FoxO phosphorylation results in FoxO permanent nuclear localization, accounting for unchecked FoxO activity and constitutive expression of target genes, an anomaly that is associated with defective insulin (or IGF-1) signaling in the pathogenesis of diseases including cancer and diabetes (Accili & Arden 2004, Altomonte et al. 2004, Barthel et al. 2005, Matsumoto et al. 2006, Qu et al. 2006, Sparks & Dong 2009, Cifarelli et al. 2012).
Mechanism of FoxO nucleocytoplasmic trafficking
Although the nucleocytoplasmic shuttling constitutes a compartmental effect for insulin (or IGF-1) to curb FoxO transcriptional activity in cells (Accili & Arden 2004, Kamagate & Dong 2008), the underlying mechanism remains elusive. Using FoxO1 as an example, Kim and coworkers (Kim et al. 2011) show that FoxO1 is capable of interacting with chromosome region maintenance 1 (CRM-1), also known as exportin-1 that is responsible for binding to the nuclear export signal (NES) of a cargo protein and transporting the cargo protein from the nucleus to cytoplasm (Dong et al. 2009, Monecke et al. 2009). Consistent with this observation is the presence of a highly conserved NES motif in the carboxyl domain of FoxO1. Immunocytochemistry reveals that FoxO1 and CRM-1 are co-localized in the nucleus of cultured hepatocytes. In response to insulin, FoxO1 in complex with CRM-1 is translocated from the nucleus to the cytoplasm. This insulin-dependent FoxO1 and CRM-1 translocation is abrogated by leptomycin B, an agent that binds specifically to CRM-1 and disables its cargo-trafficking activity (Kim et al. 2011). These results characterize CRM-1 as a mediator in facilitating insulin-dependent FoxO1 subcellular redistribution. A prevailing view is that all FoxO proteins including its orthologs dFoxO and Daf16, except for FoxO6, undergo insulin (or IGF-1)-mediated nucleocytoplasmic trafficking in cells.
FoxO integration of oxidative stress to cell survival
FoxO proteins and orthologs (dFoxO and Daf16) play important roles in protecting cells from oxidative stress. This cytoprotective effect is attributable to FoxO anti-oxidative function. In response to oxidative stress, FoxO proteins undergo translocation from the cytoplasm to the nucleus, contributing to increased FoxO activity in promoting FoxO target genes encoding anti-oxidative enzymes such as manganese superoxide dismutase (MnSOD) expression, catalase (CAT) and glutathione peroxidase (GPX). This effect contributes to the preservation of cell survival and function in the face of oxidative stress (Kops et al. 2002). However, chronic oxidative stress is also associated with cellular apoptosis. Lehtinen and coworkers show that the oxidative stress-regulated mammalian sterile 20-like kinas-1 (MST1) is activated in neuronal cells (Lehtinen et al. 2006). Activated MST1 kinases phosphorylate FoxO3 at a conserved site Ser 207 within FoxO3 forkhead box domain. The resulting effect disrupts FoxO3 interaction with 14-3-3 proteins and promotes FoxO3 nuclear translocation and stimulates apoptotic gene expression, thereby inducing death in neurons (Lehtinen et al. 2006). These data characterize MST1 as a significant upstream regulator of FoxO activity and cell surivival in response to oxidative stress.
It is noteworthy that increased MST1 activity, resulting from oxidative stress, also regulates the p38 AMPK and c-Jun N-terminal kinase (JNK) pathway (Graves et al. 1998). Essers and coworkers demonstrate that the small GTPase Ral is activated in cells in the presene of H2O2-induced oxidative stress, and this results in JNK-dependent phosphorylation of FoxO4 on Thr-447 and Thr-451 (Essers et al. 2004). This signaling pathway is also employed by tumor necrosis factor alpha (TNF-α) to activate FoxO4 activity in response to inflammation. As a result, JNK-mediated phosphorylation of FoxO4 promotes its nuclear translocation and enhances its transcriptional activity in driving the expression of anti-oxidative functions including MnSOD, CAT and GPX, protecting mammalian cells from oxidative damage (Essers et al. 2004). Interestingly, such an anti-oxidative function of FoxO1 is conserved from C. elegans to mammals.
Further physiological underpinning for the cytoprotective role of FoxO in defending oxidative stress derives from a number of significant studies in pancreatic β-cells: a cell type that is associated with extremely low expression of anti-oxidative enzymes. This renders β-cells more vulnerable to oxidative stress, accounting in part for β-cell dysfunction in diabetes. In this context, Zhang and coworkers show that FoxO1 stimulates β-cell expression of Sod1, catalase (Cat) and glutathione peroxidase 1 (Gpx1), contributing to improved β-cell survival and function in the presence of oxidative stress (Zhang et al. 2016). Kibbe and coworkers report that FoxO1 protects β-cells from oxidative stress by inhibiting the expression of thioredoxin-interacting protein (TXNIP), a cytosolic factor whose deregulation is associated with β-cell apoptosis (Kibbe et al. 2013). FoxO1 also promotes the expression of DNA repair enzyme GADD45α, protecting β-cells from nitric oxide-elicited DNA damage (Kitamura et al. 2005). Taken together, FoxO confers an evolutionally conserved cytoprotective effect on cell survival and function.
FoxO6 mediates insulin action via a distinct mechanism
FoxO6 is located on chromosome 1 (1p34.1) in humans, which is different from FoxO1 on chromosome 13 (13q14.1), FoxO3 on chromosome 6 (6q21) and FoxO4 on chromosome X (Xq13.1). Although catagoried in the FoxO family, FoxO6 has the lowest degree of homology (~30%) in amino acid sequence with other FoxO isoforms, consistent with the idea that FoxO6 is functionally divergent from the FoxO subfamily (Wang et al. 2009). FoxO6 is evoluationally conserved across the species ranging from the frogs to humans (Fig. 2), foreboding the physioloigcal importance of FoxO6 in health and disease. Indeed, characterization of FoxO6 in insulin signaling reveals that FoxO6 mediates insulin action on target gene expression via a district mechanism that is fundamentally different from other FoxO isoforms. Unlike other FoxO members that undergo insulin-mediated nucleocytoplasmic shuttling, FoxO6 remains in the nucleus of cultured cells irrespective of the addition of insulin into culture medium (Jacobs et al. 2003, Kim et al. 2011). Likewise, FoxO6 localizes in the nucleus of hepatocytes in mice, independently of fasting or refeeding state (Kim et al. 2011). In accordance with these observations, FoxO6 lacks the consensus NES motif, correlating with the inability to undergo insulin-dependent nucleocytoplasmic trafficking. Nonetheless, FoxO6 is highly sensitive to insulin inhibition in cells. These observations raise a fundamental question as to how FoxO6 mediates the inhibitory effect of insulin on target gene expression.
FoxO6 is evolutionally conserved across the species. Amino acid sequences of FoxO6 proteins were aligned in different species. The conserved amino acids corresponding to the nuclear localization signal (NLS) and Akt/PKB phosphorylation sites Thr26 and Ser184 are marked in red box.
Citation: Journal of Endocrinology 233, 2; 10.1530/JOE-17-0002
To address this issue, Kim and coworkers (Kim et al. 2011) show that FoxO6 interacts with the multifunctional protein 14-3-3 in the nucleus of hepatocytes, coinciding with the conservation of a consensus 14-3-3-binding motif (23RSCTWP28) within the FoxO6 DNA-binding domain (Fig. 1). This effect depends on insulin-stimulated FoxO6 phosphorylation at two consensus Akt/PKB phosphorylation sites Thr26 and Ser184, one of which resides within the 14-3-3 binding motif. Thus, one potential mechanism by which insulin inhibits FoxO6 transcriptional activity in the nucleus is by insulin-stimulated phosphorylation of FoxO6 proteins. This effect distorts the FoxO6 DNA-binding domain and prevents FoxO6 from binding to target promoters. As an alternative mechanism, FoxO6, when phosphorylated by Akt/PKB in response to insulin, interacts with 14-3-3, a scaffolding protein that prevents FoxO6 from binding to target promoters. There is evidence that FoxO1 adopts a similar mechanism for mediating the inhibitory action of insulin in cells. When phosphorylated in response to insulin, FoxO1 forms a complex with 14-3-3, which masks FoxO1 DNA-binding motif and precludes FoxO1 binding to target promoters. Furthermore, 14-3-3 serves as an anchor to sequester FoxO1 in the cytoplasm, preventing FoxO1 from re-entering into the nucleus (Accili & Arden 2004, Barthel et al. 2005).
An important implication of these findings is that insulin inhibition of FoxO transcriptional activity and FoxO nucleocytoplasmic trafficking are two separate events. In support of this notion, Tsai and coworkers (Tsai et al. 2003) examined insulin-dependent phosphorylation and subcellular localization of a mutant FoxO1 with an altered NES motif. Despite its inability to undergo insulin-mediated nucleocytoplasmic trafficking, such FoxO1 mutant is subject to insulin inhibition to the same extent as its wild-type counterpart. It follows that insulin inhibition of FoxO transcriptional activity can ensue without necessarily altering FoxO subcellular redistribution, but this mechanism depends on insulin-stimulated FoxO phosphorylation.
This raises an interesting question as to why insulin promotes FoxO1, but not FoxO6, translocation from the nucleus to the cytoplasm, a compartmental effect that is sufficient, but not necessary, for insulin inhibition of FoxO1 activity. One plausible interpretation is that FoxO6 serves as a basal mechanism for adjusting the rate of hepatic gluconeogenesis for rapid adaptation to changes in physiological states. This mechanism ensures that constitutively nuclear FoxO6 can immediately prime the liver for augmented gluconeogenesis in the post-absorptive phase, in which FoxO1 is already translocated from the nucleus to the cytoplasm in response to postprandial insulin release.
The alternative explanation is that cytosolic FoxO1 proteins possess secondary functions in cells. Consistent with this interpretation, Zhao and coworkers (Zhao et al. 2010) show that FoxO1 mediates autophagy via its protein–protein interaction with Atg7 (autophagy-related protein 7) in response to cellular stress. This action, which takes place in the cytoplasm, independently of FoxO1 activity in the nucleus, influences autophagy-mediated cell death in cancer cells (Zhao et al. 2010). This observation also refutes the longstanding notion that FoxO1, after trafficking from the nucleus to the cytoplasm, is destined for proteasome-mediated degradation (Matsuzaki et al. 2003, Kato et al. 2008, Jang et al. 2016).
Insulin-dependent and -independent regulation of hepatic gluconeogenesis
Gluconeogenesis is a pivotal metabolic pathway for converting non-carbohydrate metabolites (lactate, glycerol and amino acids) to glucose in the body. A life-sustaining process, gluconeogenesis provides the sole fuel source for the brain, nervous system, testes and erythrocytes during a prolonged fast or exercise. Gluconeogenesis takes place mainly in liver and to a much lesser extent in kidney (Wahren & Ekberg 2007, Edgerton et al. 2009). In healthy individuals, hepatic gluconeogenesis accounts for up to 80% of total endogenous glucose production during a prolonged fast (Ekberg et al. 1999). Gluconeogenesis is tightly regulated by hormonal and nutritional cues. In response to postprandial insulin secretion, hepatic gluconeogenic activity is suppressed to limit glucose production. This effect serves two purposes: (i) to prevent prolonged postprandial glucose excursion and (ii) to replenish glycogen content in liver, as increased glucose influx into hepatocytes promotes the synthesis and storage of glycogen in liver after meals. Conversely, in response to reduced insulin action and elevated glucagon secretion during fasting, hepatic gluconeogenesis is stimulated, resulting in increased glucose output from liver. Such a reciprocal mechanism, orchestrated by the two opposing hormones (insulin and glucagon), is crucial for rapid adaptation of liver to metabolic shift between fed and fasting states for maintaining blood sugar levels within the physiological range (Wahren & Ekberg 2007).
Gluconeogenesis is governed by two key enzymes, phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) in liver. PEPCK functions to convert oxaloacetate to phosphoenolpyruvate and G6Pase acts to convert glucose-6-phosphate to glucose. These two hepatic enzymes catalyze the first and last steps in the gluconeogenesis pathway. Consistent with their duties in gluconeogenesis, hepatic production of PEPCK and G6Pase is inhibited by insulin in the fed state and stimulated state by glucagon under fasting conditions. However, there is anecdotal evidence that increased hepatic glucose production can occur without the induction of hepatic expression of PEPCK and G6Pase in the liver. Samuel and coworkers (Samuel et al. 2009) report that hepatic expression of both PEPCK and G6Pase mRNA levels remained unchanged, despite a significant induction of endogenous glucose production in the liver of human subjects and rats with diabetes. These results seem at variance with the dogma that hepatic PEPCK and G6Pase enzymes catalyze the rate-limiting steps in the gluconeogenesis pathway. A caveat of this study is that the conclusion dwells on the measurement of hepatic PEPCK and G6Pase expression at the mRNA levels in the liver. Thus, it remains an open question as to whether PEPCK and G6Pase protein levels and their enzymatic activities are correlated with rates of hepatic glucose production in type 2 diabetes.
Aside from its direct inhibitory effect on gluconeogenesis, insulin acts to suppress gluconeogenesis by indirect mechanisms. Consistent with this notion, Olefsky and coworkers show that in obese subjects, suppression of hepatic glucose production can occur in response to insulin infusion without an apparent increase in portal insulin concentrations (Prager et al. 1987). Recently, two independent groups report that hepatic insulin signaling is dispensable for the regulation of glucose production in the liver (O-Sullivan et al. 2015, Titchenell et al. 2015). Insulin is known to exert a potent inhibitory effect on hormone-sensitive lipase, which in turn curbs adipose tissue lipolysis and reduces the availability of free fatty acid (FFA) and glycerol (Holm et al. 2000). In parallel, insulin inhibits muscle proteolysis and restrains the release of amino acids (Liu et al. 2008). FFA is used as an energy source for gluconeogenesis, and glycerol and amino acids are precursors of gluconeogenesis. A significant reduction in FFA influx to liver along with dwindling supplies of ambient gluconeogenic substrates imparts a potent indirect inhibitory effect of insulin on hepatic gluconeogenesis (Ader & Bergman 1990). In addition, insulin acts on pancreatic α-cells to suppress glucagon release, limiting hepatic glucose output (Unger et al. 1978, Ishihara et al. 2003, Jiang & Zhang 2003). Recently, Perry and coworkers report that hepatic acetyl-CoA, derived from white adipose tissue, serves as a significant regulator of hepatic glucose production. Under fasting or insulin-resistant condition, hepatic acetyl-CoA levels become higher, fueling hepatic gluconeogenesis. This effect is acutely inhibited by insulin. Insulin suppresses lipolysis in adipose tissues to limit hepatic acetyl-CoA levels, contributing to the inhibition of glucose production in the liver (Perry et al. 2015). Thus, insulin modulates hepatic gluconeogenesis via both direct and indirect mechanisms (Ader & Bergman 1990, Cherrington 2005).
FoxO6 in hepatic glucose metabolism
Although FoxO1 is shown to play a key role in integrating insulin signaling to hepatic gluconeogenesis, FoxO1 depletion in liver does not result in abolition of hormonal regulation of gluconeogenesis in mice (Matsumoto et al. 2007). In keeping with this observation, Kamagate and coworkers (Kamagate et al. 2008) show that mice with FoxO1 loss of function in liver are associated with about 50% reduction in gluconeogenic activity in response to fasting. FoxO1 loss of function reduces, but does not abrogate the responsiveness of liver to insulin or glucagon (via cAMP) signaling, raising the plausibility that there are additional factors or compensatory mechanisms in mediating hormonal regulation of hepatic gluconeogenesis (Matsumoto et al. 2007, Kamagate et al. 2008).
In this context, Kim and coworkers (Kim et al. 2011) have characterized FoxO6 as an important regulator of hepatic gluconeogenesis in response to insulin. FoxO6 is expressed in both human and rodent livers. Hepatic FoxO6 expression is maintained at low basal levels in fed states. However, in response to prolonged fasting, hepatic FoxO6 expression and transcriptional activity is markedly induced in livers of mice in response to fasting. This effect translates into a significant induction of hepatic gluconeogenesis in fasted mice. Consistent with its role in regulating hepatic gluconeogenesis, FoxO6 targets both PEPCK and G6Pase genes for trans-activation in hepatocytes, and this action is counteracted by insulin. However, unlike FoxO1, FoxO6 is unable to undergo insulin-dependent subcellular redistribution. Instead, insulin inhibits FoxO6 activity in the nucleus by directly stimulating FoxO6 phosphorylation and disables its DNA-binding activity. Conversion of the conserved Akt/PKB phosphorylation site at Ser184 to Ala renders FoxO6 refractory to insulin inhibition, contributing to its constitutive transcriptional activity. As a result, transgenic mice expressing the constitutively active FoxO6 variant in the liver are associated with increased gluconeogenesis, contributing to the development of fasting hyperglycemia (Kim et al. 2011). In contrast, hepatic FoxO6 deficiency attenuates hepatic gluconeogenesis, resulting in fasting hypoglycemia in FoxO6-knockout mice (Calabuig-Navarro et al. 2015). Consistent with its independent role in regulating hepatic gluconeogenesis, FoxO6 depletion does not elicit a compensatory induction of hepatic FoxO1 expression or activity (Calabuig-Navarro et al. 2015). Taken together, these data have revealed a distinct mechanism by which insulin signaling through FoxO6 adjusts the rate of hepatic glucose production in response to changes in physiological states. Although it is claimed that FoxO3 and FoxO4 also participate in the gluconeogenesis pathway, hepatic FoxO3 and FoxO4 depletion did not result in further significant reduction in fasting blood glucose levels in liver-specific FoxO1-knockout mice (Haeusler et al. 2010). Thus, the independent contributions of FoxO3 or FoxO4 to insulin regulation of hepatic glucose production remain to be determined.
FoxO6 in the pathogenesis of fasting hyperglycemia in diabetes
Excessive endogenous glucose production exerts its deleterious effect on whole-body metabolism in diabetes in three fundamental ways: (1) It causes prolonged postprandial blood glucose excursion, (2) it contributes to the pathogenesis of fasting hyperglycemia and (3) it accounts in part for diminished glycogen storage in liver. Because of its importance in energy homeostasis in health and its sequelae in disease, the gluconeogenesis pathway has been a major therapeutic target site for pharmacological intervention of hyperglycemia in diabetes. Identification of FoxO6 as a significant transcription factor for conducting insulin-dependent regulation of hepatic glucose production raises the postulation that FoxO6 might be a potential target for improving glycemic control in diabetes. Consistent with this idea are the observations that hepatic FoxO6 activity becomes abnormally higher in insulin-resistant livers of dietary obese mice and diabetic db/db mice (Kim et al. 2011). Likewise, hepatic FoxO6 expression is also upregulated in insulin deficient livers of streptozotocin-induced diabetic mice (Kim et al. 2011). These data indicate that insulin deficiency or insulin resistance is invariably associated with FoxO6 dysregulation in the liver. It is anticipated that selective FoxO6 inhibition would curb hepatic glucose production and ameliorate fasting hyperglycemia in diabetes. In support of this notion, Kim and coworkers (Kim et al. 2011) show that siRNA-mediated hepatic FoxO6 knockdown results in a significant reduction in hepatic gluconeogenesis in insulin-resistant liver of diabetic db/db mice. This effect contributes to reduced fasting blood glucose levels, enhanced glucose tolerance and improved insulin sensitivity in diabetic db/db mice (Kim et al. 2011). Furthermore, Calabuig-Navarro and coworkers (Calabuig-Navarro et al. 2015) show that FoxO6-deficient mice are protected from developing fasting hyperglycemia and glucose intolerance in response to high-fat feeding.
FoxO6 in hepatic lipid metabolism
Apart from its role in mediating insulin action on hepatic gluconeogenesis and glucose metabolism, FoxO6 plays a significant role in regulating hepatic lipid metabolism. Kim and coworkers (Kim et al. 2014) show that FoxO6 transgenic mice with liver-specific FoxO6 production develop hyperlipidemia, characterized by elevated plasma triglyceride (TG) levels. To dissect the underlying mechanism, Kim and coworkers (Kim et al. 2014) demonstrate that FoxO6 promoted lipogenesis and augmented TG-rich very low-density lipoprotein (VLDL-TG) secretion. This action correlates with the ability of FoxO6 to stimulate hepatic production of microsomal triglyceride transfer protein (MTP), a lipid transfer protein (MW, 88 kDa). Produced mainly in liver and to a lesser extent in the intestine, MTP, when heterodimerized with its small subunit protein disulphide isomerase (PDI, 58 kDa) in the endoplasmic reticulum (ER), catalyzes the transfer of lipid to nascent apolipoprotein B (apoB), a rate-limiting step in the nascent assembly and secretion of VLDL and chylomicrons (Gordon et al. 1995, Hui et al. 2002, Hussain et al. 2003, Swift et al. 2003, 2005, Manchekar et al. 2004). The observation that FoxO6 promotes hepatic MTP expression, which is recapitulated in primary human and mouse hepatocytes, underscores the importance of FoxO6 in regulating hepatic VLDL-TG secretion in response to insulin or nutritional cues. It is noteworthy that FoxO1 operates a similar mechanism for conducting insulin-dependent regulation of VLDL-TG production in the liver (Kamagate et al. 2008). In response to fasting, both FoxO1 and FoxO6 activities are upregulated in the liver. It remains to be determined whether FoxO1 and FoxO6 act in synergy to promote VLDL-TG production in the liver under fasting conditions.
FoxO6 in the etiology of diabetic hypertriglyceridemia
It is well established that insulin resistance is intertwined with hypertriglyceridemia in subjects with obesity and type 2 diabetes. Nonetheless, genetic factors that mechanistically couple insulin resistance with the pathogenesis of hypertriglyceridemia are incompletely characterized (Sparks & Dong 2009, Choi & Ginsberg 2011, Sparks et al. 2012). Characterization of FoxO6 as an integrator of hepatic insulin signaling with VLDL-TG production in the liver provides important insights to the mechanism of hypertriglyceridemia. In healthy individuals, insulin signaling through FoxO6 plays a pivotal role in adjusting the rates of hepatic VLDL-TG production to maintain normal lipid homeostasis. In insulin-resistant subjects, this mechanism becomes deregulated, as evidenced by significantly elevated FoxO6 production and augmented FoxO6 activity in the liver (Kim et al. 2011). As a result, hepatic MTP expression is markedly upregulated in insulin-resistant liver. This effect along with increased FFA influx into the liver promotes excessive VLDL-TG production, contributing to the development of hypertriglyceridemia in obesity and type 2 diabetes (Kim et al. 2014).
As FoxO6 is the most recently discovered FoxO isoform, there is a lack of clinical studies about the role of FoxO6 in humans. However, there is clinical evidence that FoxO1 contributes to glucose and lipid metabolism in humans. Genetic FOXO1 variants are associated with glucose intolerance, insulin resistance and type 2 diabetes in Finnish men and Pima Indians (Mussig et al. 2009, Muller et al. 2015). In contrast, it is also reported that such a close association between FOXO1 polymorphism and type 2 diabetes is lacking in different ethical groups including Caucasian and African-Americans (Karim et al. 2006). Further clinical studies are needed to characterize the role of FoxO6 and FoxO1 in metabolic diseases.
FoxO6 in skeletal muscle
Although FoxO6 is abundantly expressed in myocytes, its role in cardiac and skeletal muscles remains largely unknown. Chung and coworkers (Chung et al. 2013) report that both FoxO6 expression and transcriptional activity are upregulated in myocytes by peroxisome-proliferator-activated receptor γ co-activator 1α (PGC-1α), a transcriptional co-factor that plays important roles in mitochondria biogenesis and fatty acid oxidation in skeletal muscle (Wu et al. 1999). PGC-1α also plays a key role in muscle fiber subtype conversion from fast-twitch to slow-twitch fibers for adaptation to oxidative metabolism in mice (Lin et al. 2002). PGC-1α binds directly to the FoxO6 promoter and stimulates FoxO6 expression in cultured myocytes as well as in skeletal muscle of mice in response to oxidative low-intensity exercise (Chung et al. 2013). Interestingly, increased FoxO6 activity in turn suppresses PGC-1α expression in myocytes, setting a feedback loop in which FoxO6 and PGC-1α interplays functionally for regulating oxidative metabolism in skeletal muscle in response to exercise (Chung et al. 2013).
FoxO6 in the brain
All FoxO proteins are abundantly expressed in the brain. However, unlike other FoxO isoforms (FoxO1, FoxO3 and FoxO4) with a broad distribution in the whole brain (Furuyama et al. 2000, Hoekman et al. 2006), FoxO6 is preferentially enriched in the hippocampus, a region that is critical for learning and memory consolidation (Jacobs et al. 2003). This has inspired the hypothesis that FoxO6 might be involved in learning and memory consolidation. Indeed, Salih and coworkers (Salih et al. 2012) show that FoxO6-knockout mice display normal learning but impaired memory consolidation. These findings suggest that FoxO6 activity in the hippocampus is required for memory consolidation and that reduced FoxO6 expression in the hippocampus may contribute to pathological age-dependent decline in memory. However, this notion seems at odds with the observation that FoxO6 expression is significantly upregulated in the brain of aged mice (Zemva et al. 2012). In contrast, FoxO6 expression is significantly downregulated in the brain of dietary obese mice. This effect has been implicated in the pathogenesis of obesity and insulin resistance associated with dementia. Nonetheless, the underlying mechanism remains unexplored. Thus, further investigation is warranted to better understand the role of FoxO1 in the brain and its impact on cognitive function in relation with aging and diabetes.
FoxO6 in longevity
The FoxO family of proteins is known to play an important role in aging. Increased FoxO activity, resulting from attenuated insulin or insulin-like growth factor signaling, constitutes a caloric restriction regimen, contributing to lifespan extension in diverse organisms. This is typified by Daf16, the FoxO ortholog that acts downstream of insulin-like signaling to regulate anti-oxidative function and longevity in C. elegans in response to environment cues (Lee et al. 2003, Murphy et al. 2003). Likewise, the FoxO ortholog dFoxO seems to integrate insulin-like growth factor to aging in Drosophila melanogaster. Giannoakou and coworkers (Giannakou et al. 2004) show that dFoxO overexpression in the fat body increases lifespan by 20–50% in female but not in male Drosophila melanogaster. This conclusion was challenged by Tatar (2005), who comment that their studies are limited to the experimental condition, under which control female flies are somewhat associated with unusually higher death rates during the time course of studies. Indeed, there is evidence that dFoxO is not required for dietary restriction-induced lifespan extension in Drosophila melanogaster, although dFoxO modulates this process (Hwangbo et al. 2004, Giannakou et al. 2008, Min et al. 2008). In a recent study, Dobson and coworkers took an opposite approach to address whether dFoxO is liable for the overnutrition-elicited reduction of lifespan in Drosophila melanogaster (Dobson et al. 2017). They demonstrate that even transient feeding with a sugar-rich diet in early adulthood could produce a long-lasting detrimental effect on subsequent survival in female flies. This effect could be ascribed to the sugar-rich diet-mediated induction of insulin-like signaling, which in turn inhibits dFoxO activity and suppresses dFoxO target genes encoding epigenetic regulators in the fat body. Their data underscore the importance of dFoxO in linking overnutrition to lifespan attenuation in Drosophila melanogaster (Dobson et al. 2017).
Among the four mammalian FoxO isoforms, only FoxO3 is consistently correlated with longevity. Clinical studies characterize the FOXO3A as a susceptibility gene for human longevity in different ethnic groups including the Japanese from Hawaii (Willcox et al. 2008), Italian (Anselmi et al. 2009), German (Flachsbart et al. 2009), Chinese (Li et al. 2009), American (Pawlikowska et al. 2009) and Jewish (Soerensen et al. 2010). Preclinical studies indicate that FoxO3 is required for the lifespan extension induced by caloric restriction in mice (Shimokawa et al. 2015). In contrast, there is a lack of association between FOXO1, FOXO4 or FOXO6 and life expectancy in humans (Kleindorp et al. 2011). Likewise, transgenic mice with FoxO1 overproduction in skeletal muscle have a similar lifespan as wild-type littermates (Chiba et al. 2009). To date, the mechanism underlying FoxO3-mediated extension of lifespan in humans or animals remains elusive and warrants in-depth investigation.
FoxO functional redundancy and divergence
Despite their structural conservation in the forkhead box domain and functional redundancy to some extent, FoxO proteins possess non-overlapping functions, in line with their variable carboxyl domains and differential tissue distributions (Wang et al. 2009). For example, FoxO1, FoxO3 and FoxO4 are expressed across the brain. In contrast, FoxO6 expression is confined to the hippocampus region. FoxO1-null mice die at embryonic day 11.5 due to defective angiogenesis and vasculogenesis in the embryos (Furuyama et al. 2004). In contrast, homozygous FoxO4- and FoxO6-knockout mice are viable (Hosaka et al. 2004, Calabuig-Navarro et al. 2015). Although FoxO3-null mice are viable, female FoxO3-null mice are associated with age-dependent infertility, due to abnormal ovarian follicular development (Castrillon et al. 2003). FoxO6-knockout mice are protected from developing fat-elicited insulin resistance and metabolic syndrome. In contrast, FoxO1, FoxO3 and FoxO4, all of which are evolutionally diverged from FoxO6, display functional redundancy in regulating hepatic glucose metabolism (Haeusler et al. 2010). These results highlight the functional divergence among the four FoxO isoforms in the body.
Conclusion
FoxO6 has emerged as a key player in glucose and lipid metabolism (Fig. 3). FoxO6 is ubiquitously expressed in mammals, characteristic of the FoxO family. FoxO6 constitutes a distinct route by which the liver orchestrates insulin-dependent regulation of gluconeogenesis and VLDL-TG production. Hepatic FoxO6 activity is increased, and this effect primes the liver for promoting glucose production and VLDL-TG secretion in response to fasting. In response to postprandial insulin secretion, hepatic FoxO6 activity is inhibited to suppress glucose production and VLDL-TG assembly in the liver and prevent excessive postprandial glucose and TG excursion. Unlike other FoxO members that undergo insulin-dependent trafficking from the nucleus to the cytoplasm, FoxO6 mediates insulin action in a distinct mechanism without altering its subcellular redistribution. Hepatic insulin signaling through FoxO6 plays pivotal role in regulating glucose and lipid homeostasis. Unchecked FoxO6 activity, resulting from insulin resistance, promotes hepatic overproduction of glucose and VLDL-TG, accounting in part for the dual pathogenesis of fasting hyperglycemia and hypertriglyceridemia in diabetes. These results characterize FoxO6 as a potential therapeutic target for treating metabolic disease. Apart from its role in the liver, FoxO6 in hippocampus seems to play an important role in memory consolidation (Fig. 3). In addition, FoxO6 appears to regulate oxidative metabolism in skeletal muscle (Fig. 3). Further studies are needed to define the distinct roles of FoxO6 in central and peripheral tissues.
FoxO6 mediates the inhibitory effect of insulin or insulin-like growth factor on target genes in central and peripheral tissues. In the liver, FoxO6 contributes to insulin-dependent regulation of gluconeogenesis via PEPCK and G6Pase. Similarly, insulin signaling through FoxO6 regulates hepatic MTP and APOB expression and modulates VLDL-TG production in the liver. FoxO6 also targets PGC1α for trans-activation, which in turns suppresses FoxO6 expression in myocytes. Such FoxO6-PGC1α feedback loop plays an important part in regulating myoblast differentiation and oxidative metabolism in skeletal muscle in response to exercise. In the brain, FoxO6 contributes to neuronal regulation of myosin 6 (Myo6), Parkinson disease protein 7 (Park7), glutamate receptor 1 (Gria1), cAMP-dependent protein kinase type I-alpha regulatory subunit (Prkar1a) and amyloid-like protein 2 (Aplp2), key functions in memory consolidation.
Citation: Journal of Endocrinology 233, 2; 10.1530/JOE-17-0002
Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.
Funding
This work was supported by NIH grant R01 DK098437.
References
Accili D & Arden KC 2004 FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117 421–426. (doi:10.1016/S0092-8674(04)00452-0)
Ader M & Bergman RN 1990 Peripheral effects of insulin dominate suppression of fasting hepatic glucose production. American Journal of Physiology 258 E1020–E1032.
Altomonte J, Cong L, Harbaran S, Richter A, Xu J, Meseck M & Dong HH 2004 Foxo1 mediates insulin action on ApoC-III and triglyceride metabolism. Journal of Clinical Investigation 114 1493–1503. (doi:10.1172/JCI200419992)
Anselmi CV, Malovini A, Roncarati R, Novelli V, Villa F, Condorelli G, Bellazzi R & Puca AA 2009 Association of the FOXO3A locus with extreme longevity in a southern Italian centenarian study. Rejuvenation Research 12 95–104. (doi:10.1089/rej.2008.0827)
Barthel A, Schmoll D & Unterman TG 2005 FoxO proteins in insulin action and metabolism. Trends in Endocrinology and Metabolism 16 183–189. (doi:10.1016/j.tem.2005.03.010)
Brent MM, Anand R & Marmorstein R 2008 Structural basis for DNA recognition by FoxO1 and its regulation by posttranslational modification. Structure 16 1407–1416. (doi:10.1016/j.str.2008.06.013)
Calabuig-Navarro V, Yamauchi J, Lee S, Zhang T, Liu YZ, Sadlek K, Coudriet GM, Piganelli JD, Jiang CL & Miller R et al. 2015 Forkhead box O6 (FoxO6) depletion attenuates hepatic gluconeogenesis and protects against fat-induced glucose disorder in mice. Journal of Biological Chemistry 290 15581–15594. (doi:10.1074/jbc.M115.650994)
Castrillon DH, Miao L, Kollipara R, Horner JW & DePinho RA 2003 Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science 301 215–218. (doi:10.1126/science.1086336)
Cherrington AD 2005 The role of hepatic insulin receptors in the regulation of glucose production. Journal of Clinical Investigation 115 1136–1139. (doi:10.1172/JCI200525152)
Chiba T, Kamei Y, Shimizu T, Shirasawa T, Katsumata A, Shiraishi L, Sugita S, Ogawa Y, Miura S & Ezaki O 2009 Overexpression of FOXO1 in skeletal muscle does not alter longevity in mice. Mechanisms of Ageing and Development 130 420–428. (doi:10.1016/j.mad.2009.04.004)
Choi SH & Ginsberg HN 2011 Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends in Endocrinology and Metabolism 22 353–363. (doi:10.1016/j.tem.2011.04.007)
Chung SY, Huang WC, Su CW, Lee KW, Chi HC, Lin CT, Chen ST, Huang KM, Tsai MS & Yu HP et al. 2013 FoxO6 and PGC-1alpha form a regulatory loop in myogenic cells. Bioscience Reports 33 485–497. (doi:10.1042/bsr20130031)
Cifarelli V, Lee S, Kim DH, Zhang T, Kamagate A, Slusher S, Bertera S, Luppi P, Trucco M & Dong HH 2012 FOXO1 mediates the autocrine effect of endothelin-1 on endothelial cell survival. Molecular Endocrinology 26 1213–1224. (doi:10.1210/me.2011-1276)
Dobson AJ, Ezcurra M, Flanagan CE, Summerfield AC, Piper MD, Gems D & Alic N 2017 Nutritional programming of lifespan by FOXO inhibition on sugar-rich diets. Cell Reports 18 299–306. (doi:10.1016/j.celrep.2016.12.029)
Dong X, Biswas A, Suel KE, Jackson LK, Martinez R, Gu H & Chook YM 2009 Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature 458 1136–1141. (doi:10.1038/nature07975)
Edgerton DS, Johnson KM & Cherrington AD 2009 Current strategies for the inhibition of hepatic glucose production in type 2 diabetes. Frontiers in Bioscience 14 1169–1181. (doi:10.2741/3301)
Ekberg K, Landau BR, Wajngot A, Chandramouli V, Efendic S, Brunerngraber H & Wahren J 1999 Contributions by kidney and liver to glucose production in the postabsorptive state and after 60 h of fasting. Diabetes 48 292–298. (doi:10.2337/diabetes.48.2.292)
Essers MA, Weijzen S, de Vries-Smits AM, Saarloos I, de Ruiter ND, Bos JL & Burgering BM 2004 FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO Journal 23 4802–4812. (doi:10.1038/sj.emboj.7600476)
Essers MA, de Vries-Smits LM, Barker N, Polderman PE, Burgering BM & Korswagen HC 2005 Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science 308 1181–1184. (doi:10.1126/science.1109083)
Flachsbart F, Caliebe A, Kleindorp R, Blanche H, von Eller-Eberstein H, Nikolaus S, Schreiber S & Nebel A 2009 Association of FOXO3A variation with human longevity confirmed in German centenarians. PNAS 106 2700–2705. (doi:10.1073/pnas.0809594106)
Furuyama T, Nakazawa T, Nakano I & Mori N 2000 Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues. Biochemical Journal 349 629–634. (doi:10.1042/bj3490629)
Furuyama T, Kitayama K, Shimoda Y, Ogawa M, Sone K, Yoshida-Araki K, Hisatsune H, Nishikawa S, Nakayama K & Ikeda K et al. 2004 Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice. Journal of Biological Chemistry 279 34741–34749. (doi:10.1074/jbc.M314214200)
Giannakou ME, Goss M, Junger MA, Hafen E, Leevers SJ & Partridge L 2004 Long-lived Drosophila with overexpressed dFOXO in adult fat body. Science 305 361. (doi:10.1126/science.1098219)
Giannakou ME, Goss M & Partridge L 2008 Role of dFOXO in lifespan extension by dietary restriction in Drosophila melanogaster: not required, but its activity modulates the response. Aging Cell 7 187–198. (doi:10.1111/j.1474-9726.2007.00362.x)
Gordon DA, Wetterau JR & Gregg RE 1995 Microsomal triglyceride transfer protein: a protein complex required for the assembly of lipoprotein particles. Trends in Cell Biology 5 317–321. (doi:10.1016/S0962-8924(00)89054-6)
Graves JD, Gotoh Y, Draves KE, Ambrose D, Han DK, Wright M, Chernoff J, Clark EA & Krebs EG 1998 Caspase-mediated activation and induction of apoptosis by the mammalian Ste20-like kinase Mst1. EMBO Journal 17 2224–2234. (doi:10.1093/emboj/17.8.2224)
Haeusler RA, Kaestner KH & Accili D 2010 FoxOs function synergistically to promote glucose production. Journal of Biological Chemistry 285 35245–35248. (doi:10.1074/jbc.C110.175851)
Hoekman MF, Jacobs FM, Smidt MP & Burbach JP 2006 Spatial and temporal expression of FoxO transcription factors in the developing and adult murine brain. Gene Expression Patterns 6 134–140. (doi:10.1016/j.modgep.2005.07.003)
Holm C, Osterlund T, Laurell H & Contreras JA 2000 Molecular mechanisms regulating hormone-sensitive lipase and lipolysis. Annual Review of Nutrition 20 365–393. (doi:10.1146/annurev.nutr.20.1.365)
Hosaka T, Biggs WH, Tieu D, Boyer AD, Varki NM, Cavenee WK & Arden KC 2004 Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. PNAS 101 2975–2980. (doi:10.1073/pnas.0400093101)
Hui TY, Olivier LM, Kang S & Davis RA 2002 Microsomal triglyceride transfer protein is essential for hepatic secretion of apoB-100 and apoB-48 but not triglyceride. Journal of Lipid Research 43 785–793.
Hussain MM, Shi J & Dreizen P 2003 Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. Journal of Lipid Research 44 22–32. (doi:10.1194/jlr.R200014-JLR200)
Hwangbo DS, Gershman B, Tu MP, Palmer M & Tatar M 2004 Drosophila dFOXO controls lifespan and regulates insulin signalling in brain and fat body. Nature 429 562–566. (doi:10.1038/nature02549)
Ishihara H, Maechler P, Gjinovci A, Herrera PL & Wollheim CB 2003 Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells. Nature Cell Biology 5 330–335. (doi:10.1038/ncb951)
Jacobs FM, van der Heide LP, Wijchers PJ, Burbach JP, Hoekman MF & Smidt MP 2003 FoxO6, a novel member of the FoxO class of transcription factors with distinct shuttling dynamics. Journal of Biological Chemistry 278 35959–35967. (doi:10.1074/jbc.M302804200)
Jang H, Lee GY, Selby CP, Lee G, Jeon YG, Lee JH, Cheng KK, Titchenell P, Birnbaum MJ & Xu A et al. 2016 SREBP1c-CRY1 signalling represses hepatic glucose production by promoting FOXO1 degradation during refeeding. Nature Communications 7 12180. (doi:10.1038/ncomms12180)
Jiang G & Zhang BB 2003 Glucagon and regulation of glucose metabolism. American Journal of Physiology: Endocrinology and Metabolism 284 E671–E678. (doi:10.1152/ajpendo.00492.2002)
Kamagate A & Dong HH 2008 FoxO1 integrates insulin signaling to VLDL production. Cell Cycle 7 3162–3170. (doi:10.4161/cc.7.20.6882)
Kamagate A, Qu S, Perdomo G, Su D, Kim DH, Slusher S, Meseck M & Dong HH 2008 FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. Journal of Clinical Investigation 118 2347–2364. (doi:10.1172/jci32914)
Karim MA, Craig RL, Wang X, Hale TC & Elbein SC 2006 Analysis of FOXO1A as a candidate gene for type 2 diabetes. Molecular Genetics and Metabolism 88 171–177. (doi:10.1016/j.ymgme.2006.01.003)
Kato S, Ding J, Pisck E, Jhala US & Du K 2008 COP1 functions as a FoxO1 ubiquitin E3 ligase to regulate FoxO1-mediated gene expression. Journal of Biological Chemistry 283 35464–35473. (doi:10.1074/jbc.M801011200)
Kibbe C, Chen J, Xu G, Jing G & Shalev A 2013 FOXO1 competes with carbohydrate response element-binding protein (ChREBP) and inhibits thioredoxin-interacting protein (TXNIP) transcription in pancreatic beta cells. Journal of Biological Chemistry 288 23194–23202. (doi:10.1074/jbc.M113.473082)
Kim DH, Perdomo G, Zhang T, Slusher S, Lee S, Phillips BE, Fan Y, Giannoukakis N, Gramignoli R & Strom S et al. 2011 FoxO6 integrates insulin signaling with gluconeogenesis in the liver. Diabetes 60 2763–2774. (doi:10.2337/db11-0548)
Kim DH, Zhang T, Lee S, Calabuig-Navarro V, Yamauchi J, Piccirillo A, Fan Y, Uppala R, Goetzman E & Dong HH 2014 FoxO6 integrates insulin signaling with MTP for regulating VLDL production in the liver. Endocrinology 155 1255–1267. (doi:10.1210/en.2013-1856)
Kitamura YI, Kitamura T, Kruse JP, Raum JC, Stein R, Gu W & Accili D 2005 FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell Metabolism 2 153–163. (doi:10.1016/j.cmet.2005.08.004)
Kleindorp R, Flachsbart F, Puca AA, Malovini A, Schreiber S & Nebel A 2011 Candidate gene study of FOXO1, FOXO4, and FOXO6 reveals no association with human longevity in Germans. Aging Cell 10 622–628. (doi:10.1111/j.1474-9726.2011.00698.x)
Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, Huang TT, Bos JL, Medema RH & Burgering BM 2002 Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419 316–321. (doi:10.1038/nature01036)
Lee SS, Kennedy S, Tolonen AC & Ruvkun G 2003 DAF-16 target genes that control C. elegans life-span and metabolism. Science 300 644–647. (doi:10.1126/science.1083614)
Lehtinen MK, Yuan Z, Boag PR, Yang Y, Villen J, Becker EB, DiBacco S, de la Iglesia N, Gygi S & Blackwell TK et al. 2006 A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. Cell 125 987–1001. (doi:10.1016/j.cell.2006.03.046)
Li Y, Wang WJ, Cao HQ, Lu JH, Wu C, Hu FY, Guo J, Zhao L, Yang F & Zhang YX et al. 2009 Genetic association of FOXO1A and FOXO3A with longevity trait in Han Chinese populations. Human Molecular Genetics 18 4897–4904. (doi:10.1093/hmg/ddp459)
Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, Boss O, Michael LF, Puigserver P, Isotani E & Olson EN et al. 2002 Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418 797–801. (doi:10.1038/nature00904)
Liu Y, Dentin R, Chen D, Hedrick S, Ravnskjaer K, Schenk S, Milne J, Meyers DJ, Cole P & Yates J 3rd et al. 2008 A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature 456 269–273. (doi:10.1038/nature07349)
Manchekar M, Richardson PE, Forte TM, Datta G, Segrest JP & Dashti N 2004 Apolipoprotein B-containing lipoprotein particle assembly: lipid capacity of the nascent lipoprotein particle. Journal of Biological Chemistry 279 39757–39766. (doi:10.1074/jbc.M406302200)
Matsumoto M, Han S, Kitamura T & Accili D 2006 Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. Journal of Clinical Investigation 116 2464–2472. (doi:10.1172/JCI27047)
Matsumoto M, Pocai A, Rossetti L, Depinho RA & Accili D 2007 Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor foxo1 in liver. Cell Metabolism 6 208–216. (doi:10.1016/j.cmet.2007.08.006)
Matsuzaki H, Daitoku H, Hatta M, Tanaka K & Fukamizu A 2003 Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. PNAS 100 11285–11290. (doi:10.1073/pnas.1934283100)
Min KJ, Yamamoto R, Buch S, Pankratz M & Tatar M 2008 Drosophila lifespan control by dietary restriction independent of insulin-like signaling. Aging Cell 7 199–206. (doi:10.1111/j.1474-9726.2008.00373.x)
Monecke T, Guttler T, Neumann P, Dickmanns A, Gorlich D & Ficner R 2009 Crystal structure of the nuclear export receptor CRM1 in complex with Snurportin1 and RanGTP. Science 324 1087–1091. (doi:10.1126/science.1173388)
Mueller MM, Castells-Roca L, Babu V, Ermolaeva MA, Muller RU, Frommolt P, Williams AB, Greiss S, Schneider JI & Benzing T et al. 2014 DAF-16/FOXO and EGL-27/GATA promote developmental growth in response to persistent somatic DNA damage. Nature Cell Biology 16 1168–1179. (doi:10.1038/ncb3071)
Muller YL, Hanson RL, Wiessner G, Nieboer L, Kobes S, Piaggi P, Abdussamad M, Okani C, Knowler WC & Bogardus C et al. 2015 Assessing FOXO1A as a potential susceptibility locus for type 2 diabetes and obesity in American Indians. Obesity 23 1960–1965. (doi:10.1002/oby.21236)
Murphy CT, McCarroll SA, Bargmann CI, Fraser A, Kamath RS, Ahringer J, Li H & Kenyon C 2003 Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature 424 277–283. (doi:10.1038/nature01789)
Mussig K, Staiger H, Machicao F, Stancakova A, Kuusisto J, Laakso M, Thamer C, Machann J, Schick F & Claussen CD et al. 2009 Association of common genetic variation in the FOXO1 gene with beta-cell dysfunction, impaired glucose tolerance, and type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 94 1353–1360. (doi:10.1210/jc.2008-1048)
O-Sullivan I, Zhang W, Wasserman DH, Liew CW, Liu J, Paik J, DePinho RA, Stolz DB, Kahn CR & Schwartz MW et al. 2015 FoxO1 integrates direct and indirect effects of insulin on hepatic glucose production and glucose utilization. Nature Communications 6 7079. (doi:10.1038/ncomms8079)
Pawlikowska L, Hu D, Huntsman S, Sung A, Chu C, Chen J, Joyner AH, Schork NJ, Hsueh WC & Reiner AP et al. 2009 Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging Cell 8 460–472. (doi:10.1111/j.1474-9726.2009.00493.x)
Perry RJ, Camporez JP, Kursawe R, Titchenell PM, Zhang D, Perry CJ, Jurczak MJ, Abudukadier A, Han MS & Zhang XM et al. 2015 Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell 160 745–758. (doi:10.1016/j.cell.2015.01.012)
Prager R, Wallace P & Olefsky JM 1987 Direct and indirect effects of insulin to inhibit hepatic glucose output in obese subjects. Diabetes 36 607–611. (doi:10.2337/diab.36.5.607)
Qu S, Altomonte J, Perdomo G, He J, Fan Y, Kamagate A, Meseck M & Dong HH 2006 Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism. Endocrinology 147 5641–5652. (doi:10.1210/en.2006-0541)
Salih DA, Rashid AJ, Colas D, de la Torre-Ubieta L, Zhu RP, Morgan AA, Santo EE, Ucar D, Devarajan K & Cole CJ et al. 2012 FoxO6 regulates memory consolidation and synaptic function. Genes and Development 26 2780–2801. (doi:10.1101/gad.208926.112)
Samuel VT, Beddow SA, Iwasaki T, Zhang XM, Chu X, Still CD, Gerhard GS & Shulman GI 2009 Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with type 2 diabetes. PNAS 106 12121–12126. (doi:10.1073/pnas.0812547106)
Shimokawa I, Komatsu T, Hayashi N, Kim SE, Kawata T, Park S, Hayashi H, Yamaza H, Chiba T & Mori R 2015 The life-extending effect of dietary restriction requires Foxo3 in mice. Aging Cell 14 707–709. (doi:10.1111/acel.12340)
Soerensen M, Dato S, Christensen K, McGue M, Stevnsner T, Bohr VA & Christiansen L 2010 Replication of an association of variation in the FOXO3A gene with human longevity using both case-control and longitudinal data. Aging Cell 9 1010–1017. (doi:10.1111/j.1474-9726.2010.00627.x)
Sparks DJ & Dong HH 2009 FoxO1 and hepatic lipid metabolism. Current Opinion in Lipidology 20 217–226. (doi:10.1097/MOL.0b013e32832b3f4c)
Sparks JD, Sparks CE & Adeli K 2012 Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arteriosclerosis, Thrombosis, and Vascular Biology 32 2104–2112. (doi:10.1161/ATVBAHA.111.241463)
Swift LL, Zhu MY, Kakkad B, Jovanovska A, Neely MD, Valyi-Nagy K, Roberts RL, Ong DE & Jerome WG 2003 Subcellular localization of microsomal triglyceride transfer protein. Journal of Lipid Research 44 1841–1849. (doi:10.1194/jlr.M300276-JLR200)
Swift LL, Jovanovska A, Kakkad B & Ong DE 2005 Microsomal triglyceride transfer protein expression in mouse intestine. Histochemistry and Cell Biology 123 475–482. (doi:10.1007/s00418-005-0772-7)
Tatar M 2005 Comment on ‘long-lived Drosophila with overexpressed dFOXO in adult fat body’. Science 307 675; author reply 675. (doi:10.1126/science.1104721)
Titchenell PM, Chu Q, Monks BR & Birnbaum MJ 2015 Hepatic insulin signalling is dispensable for suppression of glucose output by insulin in vivo. Nature Communications 6 7078. (doi:10.1038/ncomms8078)
Tsai WC, Bhattacharyya N, Han LY, Hanover JA & Rechler MM 2003 Insulin inhibition of transcription stimulated by the forkhead protein Foxo1 is not solely due to nuclear exclusion. Endocrinology 144 5615–5622. (doi:10.1210/en.2003-0481)
Unger RH, Dobbs RE & Orci L 1978 Insulin, glucagon, and somatostatin secretion in the regulation of metabolism. Annual Review of Physiology 40 307–343. (doi:10.1146/annurev.ph.40.030178.001515)
Wahren J & Ekberg K 2007 Splanchnic regulation of glucose production. Annual Review of Nutrition 27 329–345. (doi:10.1146/annurev.nutr.27.061406.093806)
Wang M, Zhang X, Zhao H, Wang Q & Pan Y 2009 FoxO gene family evolution in vertebrates. BMC Evolutionary Biology 9 222. (doi:10.1186/1471-2148-9-222)
Willcox BJ, Donlon TA, He Q, Chen R, Grove JS, Yano K, Masaki KH, Willcox DC, Rodriguez B & Curb JD 2008 FOXO3A genotype is strongly associated with human longevity. PNAS 105 13987–13992. (doi:10.1073/pnas.0801030105)
Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti S, Lowell B & Scarpulla RC et al. 1999 Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98 115–124. (doi:10.1016/S0092-8674(00)80611-X)
Zemva J, Schilbach K, Stohr O, Moll L, Franko A, Krone W, Wiesner RJ & Schubert M 2012 Central FoxO3a and FoxO6 expression is down-regulated in obesity induced diabetes but not in aging. Experimental and Clinical Endocrinology and Diabetes 120 340–350. (doi:10.1055/s-0031-1297970)
Zhang T, Kim DH, Xiao X, Lee S, Gong Z, Muzumdar R, Calabuig-Navarro V, Yamauchi J, Harashima H & Wang R et al. 2016 FoxO1 plays an important role in regulating beta-cell compensation for insulin resistance in male mice. Endocrinology 157 1055–1070. (doi:10.1210/en.2015-1852)
Zhao Y, Yang J, Liao W, Liu X, Zhang H, Wang S, Wang D, Feng J, Yu L & Zhu WG 2010 Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. Nature Cell Biology 12 665–675. (doi:10.1038/ncb2069)
